PITTSBURGH–(BUSINESS WIRE)–Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, announced that Larry Brown, Sc.D., the company’s Executive Vice President and Chief Scientific Officer, will co-lead a workshop entitled, “Bypassing the BBB for More Effective Delivery to the Brain” at the digital Blood-Brain Barrier Summit on Monday, August 31, 2020 at 1:00 PM – 3:00 PM EDT.
The workshop will provide an evaluation of intranasal and intrathecal delivery routes of drug administration for brain targeting. Dr. Brown will discuss Noveome’s targeted intranasal program, including preclinical research and how those data support clinical indications using this novel drug delivery approach. Noveome is currently conducting a Phase 1 trial using a targeted intranasal device to deliver its lead product candidate, ST266, directly to the brain and eye. This trial is being conducted at The University of Pennsylvania.
About ST266
ST266 is a cell-free platform biologic containing hundreds of proteins and other factors in physiologic levels that are involved in cellular healing, protection of the brain and nerves, and modulation of inflammation. ST266 is the first potential therapeutic focused on treating the underlying nerve degeneration that occurs in glaucoma, optic nerve and retinal diseases and injuries using an innovative, non-invasive, targeted intranasal device to deliver ST266 directly to the optic nerve and eye, by-passing the blood-brain barrier. Noveome has multiple successful preclinical studies available for reference. Topline data from Noveome’s Phase 1 open-label clinical trial in Glaucoma Suspect patients are expected in the fourth quarter of 2020.
About Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics, Inc. (Read more…) is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. In addition to the Phase 1 trial described above, the company recently announced the results of a Phase 2 open-label clinical trial evaluating ST266 as a treatment for persistent Corneal Epithelial Defects (PEDs). ST266 was found to be both safe and beneficial in treating PEDs. Additional clinical trials for ophthalmological indications are being planned, including a Phase 2b PED trial and a Phase 2 wet Age-related Macular Degeneration trial. Noveome recently initiated a clinical program to evaluate the ability of ST266 to treat the severe inflammatory response called “cytokine storm” that occurs in some COVID-19 patients. This Phase 1 intravenous trial on COVID-19 patients is expected to begin in the first quarter of 2021. To date, Noveome has received over $160 million in research and infrastructure funding. Noveome is based in Pittsburgh, PA. For more information, please visit, www.noveome.com.
Contacts
Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie.seidel@sternir.com
Media Contact:
Erik Clausen
CG Life
781-608-7091
noveome@cglife.com